Key Highlights

  • Rein Therapeutics said the FDA has granted Fast Track Designation to LTI-03 for the treatment of idiopathic pulmonary fibrosis, a chronic and fatal lung disease.
  • Fast Track designation allows for more frequent FDA interactions during development and the ability to submit a Marketing application on a rolling basis, with potential eligibility for Accelerated Approval and Priority Review.
  • The company is actively enrolling patients in its Phase 2 RENEW trial evaluating LTI-03 and remains on track to report interim data in the second half of 2026.
  • LTI-03 has also previously received Orphan Drug designation from the FDA for the same indication.

FDA Grants Fast Track Status Amid Ongoing Phase 2 Trial

Rein Therapeutics (NASDAQ:RNTX) said the FDA has granted Fast Track designation to LTI-03 for the treatment of idiopathic pulmonary fibrosis, or IPF. Fast Track designation is an FDA process intended to facilitate development and expedite review of drugs that treat serious conditions and address unmet medical needs, with the aim of bringing important new therapies to patients sooner. Drugs with the designation may be eligible for more frequent interactions and written communication with the FDA throughout development, along with the ability to submit a marketing application on a rolling basis. Programs with Fast Track status may also be considered for Accelerated Approval and Priority Review if applicable regulatory criteria are met.

Brian Windsor, President and Chief Executive Officer of Rein Therapeutics, said the designation marks a significant milestone for the company and underscores the need for new treatment Options that can potentially halt disease progression and support tissue repair. He said the company's Phase 2 RENEW trial is well underway across five countries, providing an opportunity to work closely with the FDA to potentially accelerate LTI-03's development and review, and that the company remains on track to report interim trial data in the second half of the year.

IPF Remains a Disease With Limited Treatment Options

IPF is a chronic, progressive, and fatal lung disease in which scar tissue accumulates in the lungs, progressively impairing the ability to breathe. Approved therapies can slow the disease in some patients but do not halt or reverse it, and median survival following diagnosis is approximately three to five years. LTI-03 has previously received Orphan Drug designation from the FDA for the treatment of IPF.

LTI-03 is a first-in-class, inhaled peptide therapy derived from Caveolin-1 biology, a key regulator of fibrotic signaling. The drug is designed to inhibit lung scarring while preserving alveolar progenitor cells considered critical for tissue repair and regeneration. Early data suggest LTI-03 may offer a dual-acting approach, slowing fibrosis while also promoting lung healing.

RENEW Trial Spans Five Countries, Targets 120 Patients

The Phase 2 RENEW trial is a randomized, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of LTI-03 in IPF patients. The trial is expected to enroll approximately 120 patients across the United States, United Kingdom, Australia, Poland, and Germany, with patients randomized to one of two LTI-03 dose levels or placebo. The primary endpoint is safety, measured by the incidence of treatment-emergent adverse events through week 24, while change from baseline in forced vital capacity serves as the primary efficacy endpoint.

Conclusion

The Fast Track designation adds a regulatory pathway advantage to a therapy that already carries Orphan Drug status, potentially shortening the review timeline if LTI-03 continues to demonstrate safety and efficacy through the RENEW trial. With interim data expected in the second half of 2026, the coming months are likely to be a key inflection point for gauging whether the drug's early dual-acting profile, slowing fibrosis while supporting lung repair, holds up in a larger, controlled patient population.